TScan Therapeutics (TCRX) Return on Sales (2020 - 2025)
TScan Therapeutics (TCRX) has disclosed Return on Sales for 6 consecutive years, with 8.95% as the latest value for Q4 2025.
- On a quarterly basis, Return on Sales rose 4326.0% to 8.95% in Q4 2025 year-over-year; TTM through Dec 2025 was 5.53%, a 3936.0% increase, with the full-year FY2025 number at 12.57%, up 3232.0% from a year prior.
- Return on Sales was 8.95% for Q4 2025 at TScan Therapeutics, down from 8.17% in the prior quarter.
- In the past five years, Return on Sales ranged from a high of 2.72% in Q4 2023 to a low of 59.07% in Q2 2024.
- A 5-year average of 14.96% and a median of 6.31% in 2021 define the central range for Return on Sales.
- Peak YoY movement for Return on Sales: tumbled -5143bps in 2024, then surged 4489bps in 2025.
- TScan Therapeutics' Return on Sales stood at 4.98% in 2021, then fell by -22bps to 6.05% in 2022, then surged by 55bps to 2.72% in 2023, then plummeted by -1820bps to 52.21% in 2024, then surged by 83bps to 8.95% in 2025.
- Per Business Quant, the three most recent readings for TCRX's Return on Sales are 8.95% (Q4 2025), 8.17% (Q3 2025), and 14.18% (Q2 2025).